Catalog # |
Size |
Price |
|
---|---|---|---|
FEK-070-94 | 96 wells | $624 |
View/Download (PDF) - for reference only | |||||||||||||||||||||
To reduce background noise for this kit, do not add EDTA to your samples. Heparin can be used as an alternative to EDTA for this kit.
| Recommended | ||||||||||||||||||||
Data may differ slightly based on lot. | 11.2 pg/ml | ||||||||||||||||||||
Data may differ slightly based on lot. | 11.2 - 273 pg/ml | ||||||||||||||||||||
| |||||||||||||||||||||
| <10% | ||||||||||||||||||||
| <15% | ||||||||||||||||||||
| 325 nm | ||||||||||||||||||||
| 420 nm | ||||||||||||||||||||
| To reduce background noise for this kit, do not add EDTA to your samples.Heparin can be used as an alternative to EDTA for this kit. |
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet.
Athauda D, Maclagan K, Skene SS, et al. 2017;390(10103):1664-1675.
Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.
Wang Y, Xu B, Zhu L, et al. Clin Drug Investig. 2017;37(12):1107-1115.
A noncytolytic antibody-like extendin-4-IgG4 fusion protein as a long-acting potential anti-diabetic agent.
Li X, Hu P, Yang R, et al. International Journal of Clinical and Experimental Medicine. 2015;8(3):3607-3618.
Combination of ELISA and dried blood spot technique for the quantification of large molecules using exenatide as a model.
Lin YQ, Khetarpal R, Zhang Y, Song H, Li SS. J Pharmacol Toxicol Methods. 2011;64(2):124-8.
Social Network Confirmation